Argenica Therapeutics (ASX:AGN) Total Equity: A$3.44 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
30 GF Score
Price A$0.14
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Total Equity?

Argenica Therapeutics ASX:AGN +12.00% 30 Total Equity is A$3.44 Mil as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Argenica Therapeutics's total equity for the quarter that ended in Dec. 2025 was A$3.44 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Argenica Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Total Equity Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
6.85 8.31 7.67 13.95 7.24

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 6.59 13.95 13.19 7.24 3.44
ASX:AGN
30GF Score
Argenica Therapeutics Ltd ASX:AGN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Argenica Therapeutics's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=11.039-3.802
=7.24

Argenica Therapeutics's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5.2-1.757
=3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$3.44 Mil mean?
Argenica Therapeutics (ASX:AGN) has a Total Equity of A$3.44 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Argenica Therapeutics and its competitors.
Is Argenica Therapeutics' Total Equity too high?
Argenica Therapeutics' current Total Equity is A$3.44 Mil. Overall, Argenica Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Total Equity compare to VRTX and REGN?
Argenica Therapeutics' Total Equity of A$3.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Argenica Therapeutics and its competitors. Argenica Therapeutics's current Total Equity is A$3.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Total Equity of A$3.44 Mil. The current Total Equity is A$3.44 Mil. Argenica Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Total Equity is A$3.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
30GF Score

Get the complete analysis for ASX:AGN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price